

## Regulatory fees for human medicinal products valid from 1st of January 2025

| <i>Marketing authorisation application (national)</i>  | <b>Human</b> |
|--|--------------|
| Complete dossier/well established use(WEU)/fixed combinations, Directive 2001/83/EF art. 8(3), 10a, 10b          | 494 251      |
| Hybrid/Generic/Biosimilar/Informed consent, Directive 2001/83/EF art. 10(1), 10(3), 10(4), 10c                   | 185 344      |
| Additional formulations and strengths applied at the same time   | 18 535       |
| Annex I: applications except new formulations/strengths  | 111 206      |
| Annex I (Line extension): new formulations and strenghts   | 123 564      |
| Duplicate application (applied at the same time)   | 37 068       |
| Application for registration of a traditional herbal medicinal product, with HMPC-monography                     | 185 344      |
| Application for registration of a traditional herbal medicinal product, without HMPC-monography (upon agreement) | 247 126      |
| Marketing authorisation application for natural remedies   | 247 126      |
| Withdrawal of application before procedure start – administrative fee  | 24 712       |

| <i>Variation applications and applications for renewal (national)</i>   | <b>Human</b> |
|---|--------------|
| Type IB variation which leads to changes in the SmPC, PL and labeling <sup>1 2</sup>  | 10 503       |
| Type II variation: change in therapeutic indication <sup>1 2 3</sup>  | 92 673       |
| Type II variation: change in legal status <sup>1 2</sup>  | 92 673       |
| Other type II variations <sup>1 2 4</sup>   | 15 446       |
| Renewal <sup>5</sup>  | 49 425       |
| Traditional herbal medicinal products: type II variation – change in traditional use indication <sup>1 2 3</sup>            | 27 801       |
| Traditional herbal medicinal products: type IB variation which leads to changes in the SmPC, PL and labeling <sup>1 2</sup> | 10 503       |
| Traditional herbal medicinal products; other type II variations <sup>1 2</sup>  | 15 446       |
| Traditional herbal medicinal products; renewal <sup>5</sup>   | 24 712       |

| <i>Parallell import (national)</i>      | <b>Human</b> |
|---|--------------|
| Application for marketing authorisation | 19 769       |
| Renewal <sup>5</sup>                    | 6 178        |

MRP where Norway is the RMS

| <i>Marketing authorisation application (MRP-RMS)</i>        | <b>Human</b> |
|---|--------------|
| Agreement on RMS-ship <sup>6</sup>                          | 61 781       |
| Initiating MRP, regardless of legal basis <sup>7</sup>      | 123 564      |
| Repeat use, regardless of legal basis                       | 123 564      |
| Annex I: applications except new formulations and strengths | 111 206      |
| Annex I (line extension): new formulations and strengths    | 154 453      |

| <i>Variation applications and applications for renewal (MRP-RMS)</i>  | <b>Human</b> |
|---|--------------|
| Type IB variation which leads to changes in the SmPC, PL and labeling <sup>1 2</sup>  | 13 590       |
| Type II variation: change in therapeutic indication <sup>1 2 3</sup>  | 92 673       |
| Other type II variations <sup>1 2 4</sup>   | 14 828       |
| Worksharing: change in therapeutic indication <sup>3 8</sup>  | 92 673       |
| Worksharing: type IB variation which leads to changes in the SmPC, PL and labeling <sup>1 2 8</sup>                         | 12 357       |
| Worksharing: harmonisation of SmPC  | 30 890       |
| Worksharing: other type II variations <sup>8</sup>  | 15 446       |
| Renewal <sup>5</sup>  | 49 425       |
| Traditional herbal medicinal products: type IB variation which leads to changes in the SmPC, PL and labeling <sup>1 2</sup> | 9 885        |
| Traditional herbal medicinal products: type II variations <sup>1 2</sup>  | 14 828       |
| Traditional herbal medicinal products: renewal <sup>5</sup>   | 92 673       |

MRP where Norway is CMS

| <i>Markering authorisation application (MRP-CMS)</i>  | <b>Human</b> |
|---|--------------|
| Complete dossier/well established use(WEU)/fixed combinations, Directive 2001/83/EF art. 8(3), 10a, 10b.          | 123 564      |
| Hybrid/Generic/Biosimilar/Informed consent, Directive 2001/83/EF art. 10(1), 10(3), 10(4), 10c.                   | 92 673       |
| Additional formulations and strengths applied at the same time  | 18 535       |
| Annex I: applications except new formulations and strengths   | 61 781       |
| Annex I (Line extension): New formulations and strengths  | 61 781       |
| Application for registration of a traditional herbal medicinal products, with HMPC-monography                     | 92 673       |
| Application for registration of a traditional herbal medicinal products, without HMPC-monography (upon agreement) | 123 564      |
| Withdrawal of application before procedure start – administrative fee   | 24 712       |

| <i>Endringssøknader og søknad om fornyelser (MRP-CMS)</i>   | <b>Human</b> |
|---|--------------|
| Type IB variation which leads to changes in the SmPC, PL and labeling <sup>1 2</sup>  | 8 032        |
| Type II variation: change in therapeutic indication <sup>1 2 3</sup>  | 43 247       |
| Other type II variations <sup>1 2 4</sup>   | 12 357       |
| Worksharing: change in therapeutic indication <sup>3 8</sup>  | 37 068       |
| Worksharing: type IB variation which leads to changes in the SmPC, PL and labeling <sup>1 2 8</sup>                         | 12 357       |
| Worksharing: harmonisation of SmPC  | 24 712       |
| Worksharing: other type II variations <sup>8</sup>  | 12 357       |
| Renewal <sup>5</sup>  | 21 006       |
| Traditional herbal medicinal products: type IB variation which leads to changes in the SmPC, PL and labeling <sup>1 2</sup> | 6 178        |
| Traditional herbal medicinal products: type II variations <sup>1 2</sup>  | 8 648        |
| Traditional herbal medicinal products: renewal <sup>5</sup>   | 6 178        |

DCP where Norway is the RMS

| <i>Application for marketing authorisation (DCP-RMS)</i>  | <b>Human</b> |
|---|--------------|
| Agreement on RMS-ship   | 61 781       |
| Complete dossier/well established use(WEU)/fixed combinations, Directive 2001/83/EF art. 8(3), 10a, 10b.          | 432 471      |
| Hybrid/Generic/Biosimilar/Informed consent, Directive 2001/83/EF art. 10(1), 10(3), 10(4), 10c.                   | 185 344      |
| Additional formulations and strengths applied at the same time  | 18 535       |
| Annex I: applications except new formulations and strengths   | 135 918      |
| Annex I (Line extension): new formulations and strengths  | 154 453      |
| Application for registration of a traditional herbal medicinal products, with HMPC-monography                     | 185 344      |
| Application for registration of a traditional herbal medicinal products, without HMPC-monography (upon agreement) | 308 907      |

DCP where Norway is CMS

| <i>Application for marketing authorisation (DCP-CMS)</i>  | <b>Human</b> |
|---|--------------|
| Complete dossier/well established use(WEU)/fixed combinations, Directive 2001/83/EF art. 8(3), 10a, 10b.          | 123 564      |
| Hybrid/Generic/Biosimilar/Informed consent, Directive 2001/83/EF art. 10(1), 10(3), 10(4), 10c.                   | 92 673       |
| Additional formulations and strengths applied at the same time  | 18 535       |
| Duplicate application (applied at the same time)  | 37 068       |
| Annex I: applications except new formulations/strengths   | 61 781       |
| Annex I (Line extension): new formulations/strengths  | 61 781       |
| Application for registration of a traditional herbal medicinal products, with HMPC-monography                     | 92 673       |
| Application for registration of a traditional herbal medicinal products, without HMPC-monography (upon agreement) | 123 564      |
| Withdrawal of application before procedure start – administrative fee   | 24 712       |

| <i>Homeopathic medicinal products</i>  | <b>Human</b> |
|--|--------------|
| Application for registration. The fee covers all dilutions of one pharmaceutical form of a product | 24 383       |
| Type II variation  | 1 235        |
| Renewal  | 1 235        |

| <i>Clinical studies</i>  | <b>Human</b> |
|--|--------------|
| New application – Norway as reference member state (Regulation nr. 536/2014) | 75 857       |
| New application – Norway as concerned member state (Regulation nr. 536/2014) | 32 510       |
| Variations (Directiv EC 2001/20 og Regulation nr. 536/2014)                  | 6 502        |
| Safety assessments – Norway as reference member state                        | 4 335        |
| Safety assessments – Norway as concerned member state                        | 2 167        |

| <i>Applications for WHO-certificates</i> | <b>Human</b> |
|--|--------------|
| WHO-certificate                          | 6 033        |

*Note*

- 1 For variations including several formulations and strengths of the same product, one fee is invoiced
- 2 Variations leading to other consequential variations are invoiced as one.
- 3 Not applicable for linguistic changes, moving of text or information on limited documentation on the use in children etc. These are other type II variations
- 4 Applicable for posology changes
- 5 Applicable for each Marketing Authorisation
- 6 Applicable per procedure/agreement. Non refundable
- 7 Applicable independent of legal basis for the submission
- 8 Applicable independent of legal basis for the submission

Please note:

- For grouped variations, according to Variation Regulation EC 1234/2008, the fee will be equal to the sum of each variation applicable for a fee.
- Marketing Authorisations issued without national Product Information will also be applicable for a fee
- Type IA and Type IB variations without changes to the SmPC, Patient Information Leaflet and labeling will not be charged